Biofrontera Inc (BFRI) Stock Analysis
Verdict: WATCH (do not buy)
Strong 79% gross margins and 18% revenue growth are offset by under 6 months of cash runway and severe share dilution risks.
Investment score: 46/100
Analysis as of
7-factor investment score
- Valuation: 45/100 (weight 20%)
- Financial Health: 30/100 (weight 15%)
- Technical Momentum: 75/100 (weight 15%)
- Earnings Quality: 40/100 (weight 15%)
- Insider Sentiment: 45/100 (weight 10%)
- Analyst Consensus: 55/100 (weight 10%)
- Risk-Adjusted Return: 35/100 (weight 15%)
Biofrontera Inc opportunities and risks
What speaks for BFRI
- Robust gross margins above 79% enable operational leverage as top-line sales scale.
What speaks against BFRI
- Imminent cash depletion risk within 6 months.
Peers and competitors
- IGC
- ETST
- TVRD
- TXMD
- COCP
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| BFRI | n/a | 0.4x | n/a | 84.5% | -13.8% | -40.2% |
| IGC | n/a | 25.1x | n/a | 21.9% | -702.1% | -21.7% |
| ETST | 6.9x | 0.7x | 5.3x | 53.8% | 10.8% | 6.6% |
| TVRD | n/a | 0.0x | n/a | 0.0% | 0.0% | -144.2% |
| TXMD | n/a | 7.5x | n/a | 89.9% | -6.6% | 12.7% |
| COCP | n/a | 51.8x | n/a | 205.8% | -3011.5% | -47.7% |
| Peer median | n/a | 7.5x | n/a | 53.8% | -6.6% | -21.7% |
Frequently asked questions about Biofrontera Inc (BFRI)
Is BFRI stock a good investment?
The TradeMates model rates Biofrontera Inc as WATCH (do not buy) with an investment score of 46/100. Strong 79% gross margins and 18% revenue growth are offset by under 6 months of cash runway and severe share dilution risks. This is algorithmic model output, not personal investment advice.
Is BFRI stock a buy?
The TradeMates model verdict for BFRI is WATCH (do not buy) with an investment score of 46/100. Treat this as a model signal to review, not a personal buy recommendation.